Glaxo needs long-acting HIV gamble to pay off

[cafead]

via Glaxosmithkline’s upbeat investor day yesterday appeared to convince shareholders that it is not all doom and gloom at the company, but the group now needs to put its money where its mouth is. A key test will be in HIV, and the next few years should show whether Glaxo’s move towards long-acting regimens has paid off.

article source